Literature DB >> 10071307

Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate.

P A Burch, C L Loprinzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10071307

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Androgen deprivation therapy-associated vasomotor symptoms.

Authors:  Jason M Jones; Manish Kohli; Charles L Loprinzi
Journal:  Asian J Androl       Date:  2012-01-30       Impact factor: 3.285

2.  Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB.

Authors:  Amanda R Moraska; Pamela J Atherton; Daniel W Szydlo; Debra L Barton; Philip J Stella; Kendrith M Rowland; Paul L Schaefer; James Krook; James D Bearden; Charles L Loprinzi
Journal:  J Support Oncol       Date:  2010 May-Jun

3.  A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).

Authors:  C L Loprinzi; A C Dueck; B S Khoyratty; D L Barton; S Jafar; K M Rowland; P J Atherton; G W Marsa; W H Knutson; J D Bearden; L Kottschade; T R Fitch
Journal:  Ann Oncol       Date:  2009-01-06       Impact factor: 32.976

4.  Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management.

Authors:  Petros Sountoulides; Thomas Rountos
Journal:  ISRN Urol       Date:  2013-07-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.